Press coverage about Depomed (NASDAQ:DEPO) has trended somewhat positive on Sunday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Depomed earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 45.0110320484349 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Depomed (NASDAQ:DEPO) traded up $0.27 during trading hours on Friday, hitting $8.59. 931,799 shares of the company were exchanged, compared to its average volume of 1,113,230. The company has a current ratio of 0.83, a quick ratio of 0.79 and a debt-to-equity ratio of 2.90. The company has a market capitalization of $541.28, a price-to-earnings ratio of -4.69 and a beta of 1.29. Depomed has a fifty-two week low of $4.31 and a fifty-two week high of $21.27.
Depomed (NASDAQ:DEPO) last issued its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.02. The business had revenue of $95.40 million during the quarter, compared to analyst estimates of $99.11 million. Depomed had a negative net margin of 27.73% and a negative return on equity of 51.07%. The business’s revenue was down 13.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 earnings per share. analysts forecast that Depomed will post -1.34 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on the stock. Royal Bank of Canada set a $9.00 price objective on shares of Depomed and gave the company a “hold” rating in a research note on Thursday, December 7th. Piper Jaffray Companies reiterated a “hold” rating and set a $9.00 price objective on shares of Depomed in a research note on Thursday, December 7th. ValuEngine upgraded shares of Depomed from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 5th. BidaskClub upgraded shares of Depomed from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Mizuho upgraded shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 price objective on the stock in a research note on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $11.64.
In related news, insider Arthur J. Higgins purchased 75,000 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The stock was acquired at an average price of $8.16 per share, for a total transaction of $612,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.59% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Depomed (DEPO) Receiving Somewhat Favorable Media Coverage, Report Finds” was first published by Equities Focus and is owned by of Equities Focus. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.equitiesfocus.com/2018/01/07/depomed-depo-receiving-somewhat-favorable-media-coverage-report-finds.html.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.